Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2021-04-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
监事会关于第八届监事会第十二次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review opinions on various company reports and proposals, including the 2020 annual report, 2021 first quarter report, profit distribution plan, internal control self-evaluation report, accounting error corrections, stock repurchase related to restricted shares, and guarantee continuation. The document contains detailed audit opinions and confirmations about the accuracy and compliance of these reports and proposals. It is not the reports themselves but the supervisory board's formal review and approval opinions on these reports and matters. The document length is 1864 characters, which is relatively short and more consistent with a formal review or audit opinion rather than a full annual or quarterly report. This type of document fits best under Audit Report / Information (AR), as it contains audit opinions and compliance confirmations related to financial and operational reports, but is not the full report itself nor a simple announcement. Therefore, the classification is AR with high confidence. FY 2020
2021-04-26 Chinese
独立董事关于第八届董事局第十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinions on agenda items for the 19th meeting of the 8th board of directors of Shenzhen Haier Bioengineering Co., Ltd. The agenda includes the proposal to reappoint the 2021 audit firm and the proposal on expected daily related party transactions for 2021. The document references regulatory guidelines related to independent directors and shareholder rights protection. It does not contain financial statements or detailed financial data but rather opinions and approvals related to board meeting agenda items. The document length is short (689 characters) and it is not a full audit report or annual report but an independent directors' pre-approval opinion on board matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or senior management matters.
2021-04-26 Chinese
2020年度独立董事述职报告（章卫东）
Management Reports Classification · 95% confidence The document is titled '2020年度独立董事述职报告（章卫东）' which translates to '2020 Annual Independent Director's Work Report (Zhang Weidong)'. It is a detailed report by an independent director on their duties, opinions on various board matters, compliance with laws and regulations, and participation in board committees during the year 2020. The content includes independent opinions on board resolutions, related party transactions, internal controls, audit firm appointments, and corporate governance matters. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a management-related report focusing on the independent director's role and activities, which fits the category of Management Reports (MDA). The document length is over 10,000 characters, indicating it is a full report rather than a brief announcement.
2021-04-26 Chinese
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司 2021 年第一季度报告全文" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2021 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, and management commentary on financial performance for the first quarter of 2021. The presence of quarterly financial statements and comprehensive financial metrics indicates this is a quarterly financial report. The document length is about 15,000 characters, which is consistent with a full quarterly report rather than a brief announcement or certification. There is no indication that this is an annual report, audit report, or other filing type. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2021
2021-04-26 Chinese
2017-2019年度财务报表及附注（更新后）
Annual Report Classification · 100% confidence The document contains detailed financial statements including balance sheets, profit and loss statements, and notes for the fiscal years 2017 and 2016. It includes comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and earnings per share. The presence of full financial statements and notes for multiple years indicates this is a full annual financial report. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K).
2021-04-26 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report" for the fiscal year ending December 31, 2020. It contains detailed audit opinions on the effectiveness of the company's internal control over financial reporting, references to auditing standards, and extensive discussion of internal control systems, deficiencies, and remediation. The document is issued by an accounting firm (Grant Thornton) and addresses the shareholders. It is not a full annual report but a standalone audit report focused on internal control over financial reporting. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles related to internal controls. The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence.
2021-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.